COGT · NASDAQ · Biotechnology

Cogent Biosciences (COGT)

Develops bezuclastinib and other mutation-targeted therapies for mast-cell disease and cancer.

$31.41
After hours+0.00 (+0.01%)
At close$31.41(−3.75%)